Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience - Poll - MDSpire

Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience

  • By

  • Sara A. Scott

  • Ellen M. Marin

  • Kathryn T. Maples

  • Nisha S. Joseph

  • Craig C. Hofmeister

  • Vikas A. Gupta

  • Madhav V. Dhodapkar

  • Jonathan L. Kaufman

  • Sagar Lonial

  • Ajay K. Nooka

  • December 20, 2023

  • 0 min

Share

Original Source(s)

Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience

  • by Sara A. Scott, Ellen M. Marin, Kathryn T. Maples, Nisha S. Joseph, Craig C. Hofmeister, Vikas A. Gupta, Madhav V. Dhodapkar, Jonathan L. Kaufman, Sagar Lonial, Ajay K. Nooka

  • December 20, 2023

Related Content

Combination of Lisaftoclax, Ixazomib, and Dexamethasone for Maintenance Therapy Following CAR-T in Patients with Transplant-Ineligible Relapsed/Refractory Ultra-High-Risk Multiple Myeloma: A Review of Two Cases and Relevant Literature

Infection risk associated with teclistamab in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of clinical trial and real-world evidence

Assessment of the Safety and Effectiveness of CD38-Targeted CAR-T Cell Therapy in Treating Multiple Myeloma: A Systematic Review and Meta-Analysis